Innovative Cancer Detection Mercy BioAnalytics specializes in early cancer detection using a proprietary liquid biopsy platform that interrogates tumor-derived extracellular vesicles, providing opportunities to collaborate with hospitals, labs, and clinical research organizations seeking cutting-edge diagnostic solutions.

Rapid Market Expansion With recent launch of blood-based ovarian cancer testing and significant Series B funding of 59 million dollars, Mercy BioAnalytics is positioned for rapid growth and potential partnerships in oncological diagnostics across various cancer types.

Key Leadership & Talent Strategic hires of executives in commercial, program, and portfolio management along with board members with extensive clinical assay experience indicate a strong leadership team open to establishing alliances with pharmaceutical, biotech, and healthcare providers.

Recognition & Innovation Winning the Disruptive Technology Award at ADLM 2024 highlights the company's innovation capabilities, making it an attractive partner for organizations looking to adopt or integrate novel diagnostic technologies.

Technology & Data Use Mercy employs advanced digital tools and cloud-based infrastructure, such as Google Cloud and analytics platforms, indicating potential for tailored enterprise solutions and data-sharing partnerships with healthcare institutions seeking scalable diagnostic data management.